Institut Català de la Salut
[Galson JD, Schaetzle S, Kilpatrick GJ] Alchemab Therapeutics Ltd, London, United Kingdom. [Bashford-Rogers RJM] Alchemab Therapeutics Ltd, London, United Kingdom. Wellcome Centre for Human Genetics, Oxford, United Kingdom. [Raybould MIJ, Kovaltsuk A] Oxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford, United Kingdom. [Seoane J] Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-09-09T06:30:47Z
2021-09-09T06:30:47Z
2020-12-15
Repertori de cèl·lules B; SARS-CoV-2; Anticòs
Repertorio de células B; SARS-CoV-2; Anticuerpo
B-cell repertoire; SARS-CoV-2; Antibody
Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 31 COVID-19 patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2 which is consistent across patients. Clonal expansion of the B cell population is also observed and may be the result of memory bystander effects. There was a strong convergent sequence signature across patients, and we identified 1,254 clonotypes convergent between at least four of the COVID-19 patients, but not present in healthy controls or individuals following seasonal influenza vaccination. A subset of the convergent clonotypes were homologous to known SARS and SARS-CoV-2 spike protein neutralizing antibodies. Convergence was also demonstrated across wide geographies by comparison of data sets between patients from UK, USA, and China, further validating the disease association and consistency of the stereotypical immune response even at the sequence level. These convergent clonotypes provide a resource to identify potential therapeutic and prophylactic antibodies and demonstrate the potential of BCR profiling as a tool to help understand patient responses.
MR is supported by an Engineering and Physical Sciences Research Council (EPSRC) and Medical Research Council (MRC) grant (EP/L016044/1). AK is supported by a Biotechnology and Biological Sciences Research Council (BBSRC) grant (BB/M011224/1).
Article
Published version
English
COVID-19 (Malaltia); Antígens - Receptors; Seqüència de nucleòtids; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Receptors, Antigen, B-Cell; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Genetic Techniques::Sequence Analysis; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::receptores de antígenos de linfocitos B; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas genéticas::análisis de secuencias
Frontiers Media
Frontiers in Immunology;11
https://doi.org/10.3389/fimmu.2020.605170
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/